Biotech Values

[mcbio]

Re: PCYC

Whether I might ever be tempted to even remotely consider investing in PCYC depends on how thoroughly they fumigated the place after the previous management departed.

Thanks for the detailed response. I do believe the new management team was able to ink a deal with Servier for one of PCYC's HDAC inhibitors shortly after they came on board (http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=377881 ). So, they at least got off to a decent start.

PCYC owes pretty much its entire pipeline to a licensing deal it did with CRA back in 2006. See: http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=192458 . CRA will be due "mid to high single digit" royalties on the annual sales of any of the compounds. So, on a net basis, PCYC itself will likely be looking at single-digit royalties on any of these compounds if they are ultimately brought to market.